Loading clinical trials...
Loading clinical trials...
To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients. To determine the antiretroviral activity of CI-1012 when added to combination therapy. To assess the multiple-...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Parke-Davis
NCT06853314 · HIV Infections, Alcohol Use Disorder, and more
NCT05633056 · Multi Drug Resistant Tuberculosis, HIV Infections
NCT06868641 · HIV Infections
NCT06694753 · HIV Infections
NCT07559266 · HIV Infections, Mental Health, and more
ViRx Inc
Palm Springs, California
ViRx Inc
San Francisco, California
Central Florida Research Initiative
Maitland, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions